We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Possible Markers for Early Metastatic Lung Cancer Identified

Cancer cells.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

Researchers at Mays Cancer Center at The University of Texas Health Science at San Antonio (UT Health San Antonio) have identified protein markers that could signal for early development of metastatic lung cancer, providing possibilities for new treatment.


The findings already have led to a five-year, $1.6 million grant from the National Cancer Institute of the National Institutes of Health that will pave the way for a clinical trial next year for patients with advanced lung cancer. The research is detailed in a new article in Cell Reports, a peer-reviewed scientific journal publishing research papers across a broad range of disciplines within the life sciences.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“For the trial, we will be looking to recruit patients with lung adenocarcinoma, the most common primary lung cancer in the United States, and particularly those with a refractory condition for which treatment hasn’t been effective,” said Josephine A. Taverna, MD, a faculty member in hematology and oncology with Mays Cancer Center and principal investigator of the NCI/NIH grant.


She also is a lead author of the Cell Reports article titled, “AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages,” along with Tim Hui-Ming Huang, PhD, professor and chair of the Department of Molecular Medicine at UT Health San Antonio and deputy director of Mays Cancer Center.


They are joined by a team of clinical investigators at Mays Cancer Center and faculty in the departments of molecular medicine, cardiothoracic surgery, pulmonology, population health sciences and biostatistics at UT Health San Antonio, along with The University of Texas MD Anderson Cancer Center in Houston and industry partners BerGenBio and Sobi.


Tumor-associated macrophages are types of white blood cells that in dysfunctional form are integral to the development of complex tumor microenvironments, or ecosystems, promoting tumor growth, invasion, metastasis and drug resistance. Signaling of these macrophages early on for lung cancer has been elusive.


However, the research by Taverna and her colleagues indicates that certain proteins known as AXL and STAT3 together transmit signals that appear in more advanced stages of lung cancer. This signaling in tumor-associated macrophages is triggered by lung cancer cells and cancer-associated cells.


“These findings suggest the potential application of AXL-STAT3-related markers to quantitatively assess metastatic potential and inform therapeutic strategies in lung cancer,” Taverna said. “It provides a therapeutic rationale for targeting this network.”


The researchers derived their results by conducting single-cell proteomic profiling of 15 lung tumors from 13 patients with lung adenocarcinoma, one patient with squamous cell lung cancer and one patient with pleiomorphic carcinoma. They found predominant and consistent AXL-STAT3 signaling in tumor and other cancer-related cells.


“Our initial observation suggests that concomitantly high AXL/STAT3 signaling in tumor-associated macrophages may contribute to the conditioning of pro-metastatic niches,” Taverna said. “Our experiments in the lab suggest that targeting the AXL-STAT3 pathway can prevent tumor cells from recruiting tumor-associated macrophages and other aggressive host cells into the tumor microenvironment, thereby inhibiting tumor growth and spread.”


Reference: Hung CN, Chen M, DeArmond DT, et al. AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. Cell Reports. 2023;42(9):113067. doi: 10.1016/j.celrep.2023.113067


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.